Literature DB >> 831074

Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.

K V Toyka, D B Drachman, D E Griffin, A Pestronk, J A Winkelstein, K H Fishbeck, I Kao.   

Abstract

To study the role of humoral factors in the pathogenesis of myasthenia gravis, we employed passive transfer of human serum fractions to mice. Immunoglobulins from 16 patients with myasthenia gravis were injected into mice daily for one to 14 days. Typical myasthenic features of reduction in amplitude of miniature end-plate potentials (mean change more than 50 per cent, P less than 0.005) or reduction in acetylcholine receptors at neuromuscular junctions (mean change more than 50 per cent, P less than 0.005) (or both) were produced by immunoglobulin from 15 of the 16 patients. Some mice showed weakness or decremental responses to repetitive nerve stimulation as well. The active fraction was identified as IgG by three different purification methods. Its effect was enhanced by the third component (C3) of the complement system, but the fifth component (C5) had no effect. These data suggest that the pathogenesis of myasthenia gravis often involves and antibody-mediated autoimmune attack on the acetylcholine receptors of the neuromuscular junction.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 831074     DOI: 10.1056/NEJM197701202960301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  75 in total

1.  Induction of oral tolerance to the acetylcholine receptor for treatment of myasthenia gravis.

Authors:  H L Weiner
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 2.  Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.

Authors:  Goran Rakocevic; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

3.  [Myasthenia gravis and thymolipoma: a rare variation of a well-known theme].

Authors:  M Schneider; U Eichfeld; A Beller; P Baum; J Claßen; F Then Bergh
Journal:  Nervenarzt       Date:  2012-08       Impact factor: 1.214

Review 4.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

5.  Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.

Authors:  Chengyong Shen; Yisheng Lu; Bin Zhang; Dwight Figueiredo; Jonathan Bean; Jiung Jung; Haitao Wu; Arnab Barik; Dong-Min Yin; Wen-Cheng Xiong; Lin Mei
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

6.  Anti-MuSK autoantibodies block binding of collagen Q to MuSK.

Authors:  Y Kawakami; M Ito; M Hirayama; K Sahashi; B Ohkawara; A Masuda; H Nishida; N Mabuchi; A G Engel; K Ohno
Journal:  Neurology       Date:  2011-10-19       Impact factor: 9.910

7.  Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis.

Authors:  Daniel B Drachman; Robert N Adams; Rong Hu; Richard J Jones; Robert A Brodsky
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

Review 8.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

9.  Lymphocyte subpopulations and surface membrane immunoglobulins in myasthenia gravis.

Authors:  G Landi; M Galli; G Ciboddo; G Colombo; G Scarlato
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-02       Impact factor: 10.154

10.  Autoantibodies in neuromuscular transmission disorders.

Authors:  Angela Vincent
Journal:  Ann Indian Acad Neurol       Date:  2008-07       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.